Tirzepatide is a dual agonist for the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. The drug leads to significantly improved glycemic control and weight reduction in patients with T2DM, maximizing benefits similar to GLP-1 medications such as semaglutide.
Tirzepatide 10mg
Dosing & Reconstitution Guide
Educational guide for reconstitution and dosing protocol
Standard Titration Approach (1 mL = 10 mg/mL)
PHASE (WEEKS)
WEEKLY DOSE (MG)
UNITS (PER INJECTION)
Weeks 1–4
2.5 mg
25 units (0.25 mL)
Weeks 5–8
5 mg
50 units (0.50 mL)
Weeks 9–12
7.5 mg
75 units (0.75 mL)
Weeks 13–16
10 mg
100 units (1.00 mL)
Weeks 17–20
12.5 mg
125 units (1.25 mL)
(requires two injections)
Weeks 21–24
15 mg
150 units (1.50 mL)
(requires two injections)
This gradual escalation protocol aligns with the standard clinical titration for once-weekly tirzepatide. Reconstitute each 10 mg vial with 1.0 mL of bacteriostatic water (10 mg/mL). Higher doses above 10 mg per week will require multiple injections or additional vials.
Draw 1.0 mL of bacteriostatic water into a sterile syringe.
Slowly inject along the vial wall to minimize foaming.
Gently swirl—do not shake vigorously.
Store the reconstituted solution at 2–8 °C (refrigerator), protected from light.